UK biotech round-up: Autolus joins CAR-T race, Horizon’s new CRISPR tech, Allergy Therapeutics’ grass gambit – pharmaphorum
|
UK biotech round-up: Autolus joins CAR–T race, Horizon’s new CRISPR tech, Allergy Therapeutics’ grass gambit
pharmaphorum “BCMA CAR–T cell therapies have shown considerable promise in early clinical studies. A dual-targeted approach may minimise the risk for antigen negative escape and extend CAR-T treatment to patients with low density of BCMA antigen on the surface … Syncona’s Autolus begins three T-cell cancer trials | Digitallook.comDIGITALLOOK Arix Bioscience plc notes positive clinical study announcements from Autolus LimitedMarkets Insider Arix Bioscience Notes Autolus Ltd’s Updates On Clinical Progress …London South East (registration) (blog) Stock Market Wire all 4 news articles » |
|
UK biotech round-up: Autolus joins CAR–T race, Horizon’s new CRISPR tech, Allergy Therapeutics’ grass gambit
pharmaphorum “BCMA CAR–T cell therapies have shown considerable promise in early clinical studies. A dual-targeted approach may minimise the risk for antigen negative escape and extend CAR-T treatment to patients with low density of BCMA antigen on the surface … Syncona’s Autolus begins three T-cell cancer trials | Digitallook.comDIGITALLOOK Arix Bioscience plc notes positive clinical study announcements from Autolus LimitedMarkets Insider Arix Bioscience Notes Autolus Ltd’s Updates On Clinical Progress …London South East (registration) (blog) Stock Market Wire all 4 news articles » |
STAT |
There’s only one approved CAR–T, but companies are ready to capitalize on it
STAT AR-T is having a moment. Novartis (NVS 1) won the first Food and Drug Administration approval 2 in August for this class of personalized cancer treatments, beating rivals in the race 3 to sell a therapy that is custom-made with individual patients’ cells. |
|
Syncona’s Autolus begins three T–cell cancer trials
DIGITALLOOK The second most commonly diagnosed blood cancer after non-Hodgkin lymphoma, multiple myeloma is a blood cancer affecting plasma cells which can currently be treated but not cured. AUTO2 is the first dual-targeting CAR–T cell therapy in clinical … Arix Bioscience notes positive progress by AutolusStock Market Wire |
|
FDA puts hold on clinical trials for CAR–T cell therapy
BSA bureau (press release) Juno attributed the deaths to the interaction between the pre-conditioning chemo regimen —consisting of fludarabine and cyclophosphamide — and the CAR–T cells reinfused back into the patient. Cellectis and Juno have fallen behind other CAR-T … |